Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis

Abstract

Tofacitinib is an oral small-molecule Janus kinase (JAK) inhibitor that preferentially inhibits JAK1 and JAK3. Its efficacy in inducing and maintaining remission in ulcerative colitis (UC) as well as its safety profile has been demonstrated in multicenter, randomized, double-blind, placebo-controlled trials. Additionally, real-world studies evaluating the effectiveness and adverse effects of tofacitinib have been conducted, affirming its clinical efficacy in moderate-to-severe UC.

Keywords: Ulcerative colitis; Tofacitinib; Real-world studies; Inflammatory bowel disease; Janus kinase inhibitor

Core Tip: Tofacitinib, an oral small-molecule agent, has proven efficacy in inducing and maintaining remission among patients with moderate-to-severe ulcerative colitis. Real-world studies have showcased its effectiveness and safety profile to treat ulcerative colitis, primarily within Western countries. There have been a limited number of studies conducted on Asian patients.